Suppressing Apoptosis with Milrinone Simulating Extracorporeal Circulation: A Pilot Study

Abstract

Background: After cardioplegia, ischemia/reperfusion injury can induce apoptosis. The aim of this study was to evaluate our ex vivo microperfusion model on human myocardium during simulated cardioplegia (cp) and reperfusion (rep). In addition, the aim was to verify the anti-apoptotic properties of the phosphodiesterase 3 inhibitor milrinone. Methods: Cardiac biopsies were retrieved from the right auricle of patients undergoing elective CABG prior to induction of cardiopulmonary bypass. Biopsies were exposed to ex vivo conditions with varying periods of cp/rep (30/10, 60/20, 120/40 min). Group I consisted of untreated controls (n = 15), Group II of treated controls who had cp/rep (n = 15) while Group III had cp/rep + milrinone (n = 15). For the detection of apoptosis, anti-activated caspase-3 and PARP-1 cleavage immunostaining were used. Results: The percentage of apoptotic cardiomyocytes in Group I was significantly (p < 0.05) lower compared to Group II, revealing a time-dependent increase. In Group III with milrinone treatment, apoptosis was significantly suppressed (p < 0.05). Conclusions: Milrinone significantly suppressed apoptosis in our ex vivo setting. This finding warrants further study aiming to evaluate the potential beneficial effects of milrinone on the suppression of ischemia/reperfusion injury in a clinical setting.

apoptosis - cardioplegia - ischemia/reperfusion injury - milrinone - myocardial protection - coronary bypass surgery - cardiomyopathy

Reference

• 1 Schmitt J P, Schroder J, Schunkert H, Birnbaum D E, Aebert H. Role of apoptosis in myocardial stunning after open heart surgery.  Ann Thorac Surg. 2002;  73 (4) 1229-1235
• 2 Bai C X, Namekata I, Kurokawa J, Tanaka H, Shigenobu K, Furukawa T. Role of nitric oxide in Ca²⁺ sensitivity of the slowly activating delayed rectifier K+ current in cardiac myocytes.  Circ Res. 2005;  96 (1) 64-72
• 3 Murriel C L, Churchill E, Inagaki K, Szweda L I, Mochly-Rosen D. Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria.  J Biol Chem. 2004;  279 (46) 47985-47991
• 4 Burniston J G, Ellison G M, Clark W A, Goldspink D F, Tan L B. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others.  Cardiovasc Toxicol. 2005;  5 (4) 355-364
• 5 Goldstein S M, Nelson R L, McConnell D H, Buckberg G D. Effects of conventional hypothermic ischemic arrest and pharmacological arrest on myocardial supply/demand balance during aortic cross-clamping.  Ann Thorac Surg. 1977;  23 (6) 520-528
• 6 Weinlich M, Baumstark C, Usta E, Becker H D, Sessler M J. Human duodenal spheroids for noninvasive intracellular pH measurement and quantification of regulation mechanisms under physiological conditions.  In Vitro Cell Dev Biol Anim. 2002;  38 (1) 7-13
• 7 Tewari M, Quan L T, O'Rourke K et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase.  Cell. 1995;  81 (5) 801-809
• 8 Beavo J A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.  Physiol Rev. 1995;  75 (4) 725-748
• 9 Yan C, Miller C L, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.  Circ Res. 2007;  100 (4) 489-501
• 10 Shin D D, Brandimarte F, De Luca L et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes.  Am J Cardiol. 2007;  99 (2A) 4A-23A
• 11 Lehtonen L A, Antila S, Pentikainen P J. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.  Clin Pharmacokinet. 2004;  43 (3) 187-203
• 12 Chanani N K, Cowan D B, Takeuchi K et al. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling.  Circulation. 2002;  106 (12 Suppl. 1) I284-I289
• 13 Azuma M, Yamane M, Tachibana K, Morimoto Y, Kemmotsu O. Effects of epinephrine and phosphodiesterase III inhibitors on bupivacaine-induced myocardial depression in guinea-pig papillary muscle.  Br J Anaesth. 2003;  90 (1) 66-71
• 14 Fukutomi T, Satoh K, Ogoshi S, Ichihara K. Effects of pimobendan and EGIS9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs.  Coron Artery Dis. 2000;  11 (1) 83-90
• 15 Ghosh S, Ng L L, Talwar S, Squire I B, Galinanes M. Cardiotrophin-1 protects the human myocardium from ischemic injury. Comparison with the first and second window of protection by ischemic preconditioning.  Cardiovasc Res. 2000;  48 (3) 440-447
• 16 Miyamoto S, Howes A L, Adams J W, Dorn G W, Brown J H. Ca²⁺ dysregulation induces mitochondrial depolarization and apoptosis: role of Na⁺/Ca²⁺ exchanger and AKT.  J Biol Chem. 2005;  280 (46) 38505-38512
• 17 Lowe H, Jacobsohn E. Protection of the hypoxic myocardium by the bispyridine derivatives AWD 122-14 and milrinone: studies on isolated, working right rabbit hearts.  Pharmazie. 1992;  47 (6) 452-455
• 18 Shakur Y, Fong M, Hensley J et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.  Cardiovasc Drugs Ther. 2002;  16 (5) 417-427
• 19 Amos G J, Wettwer E, Metzger F, Li Q, Himmel H M, Ravens U. Differences between outward currents of human atrial and subepicardial ventricular myocytes.  J Physiol. 1996;  491 (Pt 1) 31-50
• 20 Del Monte F, Hajjar R J. Intracellular devastation in heart failure.  Heart Fail Rev. 2008;  13 (2) 151-162
• 21 Zhang J, Chen F, Zhao X et al. Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury.  J Heart Lung Transplant. 2009;  28 (1) 79-84